Hbm Healthcare Investments (Ca Sells 57,175 Shares of Nabriva Therapeutics AG (NASDAQ:NBRV) Stock

Nabriva Therapeutics AG (NASDAQ:NBRV) major shareholder Hbm Healthcare Investments (Ca sold 57,175 shares of the stock in a transaction on Thursday, July 13th. The shares were sold at an average price of $10.53, for a total value of $602,052.75. Following the completion of the sale, the insider now owns 2,565,661 shares in the company, valued at $27,016,410.33. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Major shareholders that own at least 10% of a company’s shares are required to disclose their sales and purchases with the SEC.

Hbm Healthcare Investments (Ca also recently made the following trade(s):

  • On Monday, August 7th, Hbm Healthcare Investments (Ca sold 17,790 shares of Nabriva Therapeutics AG stock. The stock was sold at an average price of $10.50, for a total value of $186,795.00.
  • On Tuesday, August 8th, Hbm Healthcare Investments (Ca sold 19,803 shares of Nabriva Therapeutics AG stock. The stock was sold at an average price of $10.50, for a total value of $207,931.50.
  • On Friday, July 28th, Hbm Healthcare Investments (Ca sold 6,585 shares of Nabriva Therapeutics AG stock. The shares were sold at an average price of $10.51, for a total transaction of $69,208.35.
  • On Monday, July 24th, Hbm Healthcare Investments (Ca sold 160 shares of Nabriva Therapeutics AG stock. The shares were sold at an average price of $10.50, for a total transaction of $1,680.00.
  • On Thursday, July 20th, Hbm Healthcare Investments (Ca sold 44,231 shares of Nabriva Therapeutics AG stock. The shares were sold at an average price of $10.50, for a total transaction of $464,425.50.
  • On Tuesday, July 18th, Hbm Healthcare Investments (Ca sold 69,854 shares of Nabriva Therapeutics AG stock. The shares were sold at an average price of $10.51, for a total transaction of $734,165.54.
  • On Friday, July 7th, Hbm Healthcare Investments (Ca sold 2,695 shares of Nabriva Therapeutics AG stock. The shares were sold at an average price of $10.52, for a total transaction of $28,351.40.
  • On Friday, June 30th, Hbm Healthcare Investments (Ca sold 1,775 shares of Nabriva Therapeutics AG stock. The shares were sold at an average price of $10.94, for a total transaction of $19,418.50.
  • On Monday, July 3rd, Hbm Healthcare Investments (Ca sold 13,127 shares of Nabriva Therapeutics AG stock. The shares were sold at an average price of $10.94, for a total transaction of $143,609.38.
  • On Thursday, June 29th, Hbm Healthcare Investments (Ca sold 8,558 shares of Nabriva Therapeutics AG stock. The shares were sold at an average price of $10.96, for a total transaction of $93,795.68.

Nabriva Therapeutics AG (NASDAQ:NBRV) traded up 2.15% on Friday, reaching $10.00. 21,541 shares of the company’s stock traded hands. The stock’s market capitalization is $268.38 million. The firm’s 50-day moving average is $10.42 and its 200 day moving average is $10.33. Nabriva Therapeutics AG has a 52-week low of $3.52 and a 52-week high of $12.75.

Nabriva Therapeutics AG (NASDAQ:NBRV) last announced its quarterly earnings results on Monday, August 7th. The biotechnology company reported ($0.54) earnings per share (EPS) for the quarter, beating the consensus estimate of ($5.83) by $5.29. The firm had revenue of $1.05 million for the quarter, compared to the consensus estimate of $1.34 million. Analysts forecast that Nabriva Therapeutics AG will post ($2.43) EPS for the current year.

COPYRIGHT VIOLATION WARNING: This article was originally reported by Community Financial News and is the sole property of of Community Financial News. If you are accessing this article on another website, it was illegally copied and reposted in violation of United States and international trademark and copyright law. The legal version of this article can be read at https://www.com-unik.info/2017/08/11/hbm-healthcare-investments-ca-sells-57175-shares-of-nabriva-therapeutics-ag-nasdaqnbrv-stock-updated-updated-updated.html.

Large investors have recently bought and sold shares of the stock. Renaissance Technologies LLC bought a new stake in Nabriva Therapeutics AG during the fourth quarter valued at $103,000. Almanack Investment Partners LLC. boosted its stake in shares of Nabriva Therapeutics AG by 482.2% in the second quarter. Almanack Investment Partners LLC. now owns 907,183 shares of the biotechnology company’s stock valued at $1,633,000 after buying an additional 751,366 shares in the last quarter. Nationwide Fund Advisors boosted its stake in shares of Nabriva Therapeutics AG by 4.6% in the second quarter. Nationwide Fund Advisors now owns 180,924 shares of the biotechnology company’s stock valued at $2,032,000 after buying an additional 7,924 shares in the last quarter. Finally, Wellington Management Group LLP boosted its stake in shares of Nabriva Therapeutics AG by 9.9% in the first quarter. Wellington Management Group LLP now owns 2,154,261 shares of the biotechnology company’s stock valued at $25,830,000 after buying an additional 193,951 shares in the last quarter. Hedge funds and other institutional investors own 56.65% of the company’s stock.

Several research analysts recently issued reports on NBRV shares. HC Wainwright restated a “buy” rating on shares of Nabriva Therapeutics AG in a research report on Friday, May 12th. Cantor Fitzgerald set a $16.00 price objective on shares of Nabriva Therapeutics AG and gave the company a “buy” rating in a research note on Monday, June 5th. ValuEngine raised shares of Nabriva Therapeutics AG from a “sell” rating to a “hold” rating in a research report on Saturday, June 24th. Wedbush reaffirmed an “outperform” rating and set a $13.00 price target on shares of Nabriva Therapeutics AG in a research report on Monday, May 15th. Finally, Zacks Investment Research upgraded shares of Nabriva Therapeutics AG from a “sell” rating to a “hold” rating and set a $12.00 price objective on the stock in a report on Tuesday, July 18th. One investment analyst has rated the stock with a sell rating and seven have given a buy rating to the company. The company presently has a consensus rating of “Buy” and a consensus price target of $15.43.

About Nabriva Therapeutics AG

Nabriva Therapeutics plc is a clinical stage biopharmaceutical company. The Company is engaged in engaged in the research and development of novel anti-infectives to treat serious infections, with a focus on the pleuromutilin class of antibiotics. The Company’s medicinal chemistry has enabled targeted discovery of novel pleuromutilins, including both intravenous and oral formulations of its lead product candidate, lefamulin.

Insider Buying and Selling by Quarter for Nabriva Therapeutics AG (NASDAQ:NBRV)

What are top analysts saying about Nabriva Therapeutics AG? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Nabriva Therapeutics AG and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit